Michael Jackson, PhD, MPH

“Group Health gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Michael L. Jackson, PhD, MPH

Group Health Research Institute Assistant Investigator

Biography

Michael L. Jackson’s research focuses  on understanding how infectious diseases spread, and on designing and evaluating  interventions such as vaccination programs. Dr. Jackson is the Group Health Research Institute (GHRI) principal  investigator for the United States Influenza Vaccine Effectiveness Network.  This Network aims to provide ongoing evaluations of the U.S. influenza  vaccination program. Dr. Jackson uses data from this Network to study influenza  vaccine effectiveness, to estimate the burden of disease caused by influenza,  and to advance the methodology of vaccine effectiveness studies. He also uses  mathematical models to predict the impact of vaccination programs on the spread  of infectious diseases such as Haemophilus  influenza type b (Hib) and Neisseria  meningitidis.

Dr. Jackson is a co-investigator on  the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration between  nine U.S. managed care organizations and the Centers for Disease Control and  Prevention (CDC), is the world’s premier system for post-licensure studies of  vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the  safety of childhood immunizations and develops methods for using managed care  data for vaccine safety studies.

While studying for his PhD at the University of  Washington, Dr. Jackson was a graduate research associate with GHRI from 2002  to 2007, and then a postdoctoral fellow at GHRI from 2007 to 2008. He then  spent two years as an Epidemic Intelligence Service (EIS)  officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead  investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He  also designed and oversaw an enhanced surveillance system for invasive Hib  disease in the U.S. during the 2008-2009 shortage of Hib vaccines. He returned  to GHRI as an assistant investigator in 2010.

Research interests and experience

 

 

 

Recent publications

Havers F, Thaker S, Clippard JR, Jackson M, Mclean H, Monto AM, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Flannery B, Thompson MG, Fry AM.

Use of influenza antiviral agents by ambulatory care clinicians during the 2012-13 influenza season.

Clin Infect Dis. 2014 Jul 16. pii: ciu422. [Epub ahead of print].

Jackson ML, Henrikson NB, Grossman DC.

Evaluating Washington State’s Immunization Information System as a research tool.

Academ Pediatr. 2014 Jan 1;14(1):71-6. doi: 10.1016/j.acap.2013.10.002.

McCarthy NL, Weintraub E, Vellozzi C, Duffy J, Gee J, Donahue JG, Jackson ML, Lee GM, Glanz J, Baxter R, Lugg MM, Naleway A, Omer SB, Nakasato C, Vazquez-Benitez G, DeStefano F.

Mortality rates and cause-of-death patterns in a vaccinated population.

Am J Prev Med. 2013;45(1):91-7. doi: 10.1016/j.amepre.2013.02.020. PubMed

Greene SK, Rett MD, Vellozzi C, Kulldorff M, Marcy SM, Daley MF, Belongia EA, Baxter R, Fireman BH, Jackson ML, Omer SB, Nordin JD, Jin R, Weintraub ES, Vijayadeva V, Lee GM.

Guillain-Barré Syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011.

PLoS One. 2013 Jun 26;8(6):e67185. Print 2013. PubMed